Status:
COMPLETED
Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848
Lead Sponsor:
AstraZeneca
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The primary purpose of this study is to investigate effect, tolerability and safety of different dosing regimens of AZD8848 administered intranasally to seasonal allergic rhinitis patients out of seas...
Detailed Description
A double-blind, placebo controlled, randomised, parallel group phase IIa study to investigate the efficacy, tolerability, and safety of different dosing regimens of AZD8848 administered intranasally t...
Eligibility Criteria
Inclusion
- Seasonal allergic rhinitis patients out of pollen season
- Have a history and presence of birch and/or timothy grass pollen induced seasonal allergic rhinitis for at least the previous 2 years (verified by a positive skin prick test)
- Patients with need of treatment for their nasal symptoms during the pollen season
Exclusion
- Symptomatic perennial allergic or non-allergic rhinitis
- Family history of autoimmune disease A history of asthma
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT01185080
Start Date
September 1 2010
End Date
January 1 2012
Last Update
January 7 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Lund, Malmohus Lan, Sweden
2
Research Site
Helsingborg, Sweden